Request Copyright Permission

The Dry Powder Route to Effective Aerosol Surfactant Therapy—A Little Can Go a Long Way

Longest P, DiBlasi RM, Momin M, Farkas DR, KenKnight H, Kontoudios N, Hall F, Dalton CJ, Aladwani G, Strickler S, Hindle M.

Respiratory Drug Delivery 2024. Volume 1, 2024: 21-31.

Abstract:

The objective of this study is to review recent progress in the development of a dry powder synthetic lung surfactant (SLS) aerosol product in the areas of in vitro performance and device refinement, in vivo animal model efficacy testing, expansion to improve performance at higher doses, and to enable efficient non-invasive delivery. We first describe the individual elements of the product and the related in vitro aerosol size characterization. We then review our work with realistic in vitro animal model testing of aerosol delivery, which was used for dose planning and to maximize efficacy of the subsequent in vivo experiments. Efficacy results are then reviewed based on testing in a preterm infant-size in vivo rabbit surfactant washout model. Finally, we present progress for improving the consistency of aerosolizing relatively high dose (20–50 mg) dry powder aerosols for administration to infants and for achieving high efficiency nose-to-lung powder aerosol delivery.